Published in Leukemia on May 01, 1995
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol (1998) 2.18
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol (2000) 2.09
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia (2007) 2.09
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood (1990) 2.04
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet (1992) 1.54
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia (2006) 1.51
Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood (1998) 1.49
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol (1990) 1.42
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.42
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol (1993) 1.42
The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med (2007) 1.40
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer (1992) 1.39
Increased levels of beta 2-glycoprotein I (aca-Cofactor) in patients with lupus anticoagulant. Thromb Haemost (1992) 1.39
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia (2007) 1.35
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 1.34
Bacterial endocarditis produced by Listeria monocytogenes. Case presentation and review of literature. Am J Clin Pathol (1975) 1.29
High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood (1991) 1.25
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) Ann Oncol (1999) 1.24
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol (2001) 1.20
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood (1999) 1.17
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia (2008) 1.15
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer (1990) 1.15
Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med (1978) 1.12
What are RBC-transfusion-dependence and -independence? Leuk Res (2010) 1.09
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood (1989) 1.08
Subunits A and S inheritance in four families with congenital factor XIII deficiency. Br J Haematol (1978) 1.08
Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol (1999) 1.07
T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. J Exp Med (1985) 1.07
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol (2000) 1.07
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (1997) 1.04
Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology (1991) 1.03
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol (1989) 1.02
Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1997) 1.02
Trends in mortality from leukemia in subsequent age groups. Leukemia (2000) 1.02
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia (2011) 1.00
Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol (1996) 1.00
All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol (1996) 0.98
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia (2003) 0.97
Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukaemia. Thromb Haemost (1980) 0.97
AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood (1996) 0.96
Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura. Br J Haematol (1994) 0.96
Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia (1999) 0.95
A new procoagulant in acute leukemia. Blood (1988) 0.95
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood (1989) 0.94
Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost (1992) 0.94
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol (1991) 0.93
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood (1984) 0.93
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med (1994) 0.92
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia (2013) 0.92
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost (1998) 0.90
Hereditary dysfunctional protein C (protein C Bergamo) and thrombosis. Lancet (1984) 0.90
Association of NK-cell lymphoproliferative disease and nephrotic syndrome. Am J Clin Pathol (1990) 0.89
Is female sex an independent predictor of in-hospital mortality in acute myocardial infarction? Arq Bras Cardiol (2001) 0.89
Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol (1989) 0.89
Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood (1999) 0.89
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood (1998) 0.88
Nosocomial outbreak of severe Pseudomonas aeruginosa infections in haematological patients. Eur J Epidemiol (1993) 0.88
Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost (1996) 0.88
Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia (2011) 0.88
Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1994) 0.87
Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer (1989) 0.87
Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost (1987) 0.87
Recurrence after first cerebral infarction in young adults. Acta Neurol Scand (2000) 0.86
Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost (1994) 0.86
A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. ad hoc Study Group. Ric Clin Lab (1991) 0.86
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med (1999) 0.85
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant (2008) 0.85
Electroimmunoassay of plasma subunits-a and -s in a case of congenital fibrin stabilizing factor deficiency. Thromb Diath Haemorrh (1974) 0.85
Transcriptional and post-transcriptional regulation of IL-1 beta, IL-6 and TNF-alpha genes in chronic lymphocytic leukaemia. Br J Haematol (1993) 0.85
The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis (1994) 0.85
ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol (2002) 0.85